All Content

The prostate cancer drug enzalutamide has shown activity in women with advanced triple-negative breast cancer whose tumors express the androgen receptor.

Data from the LUX-Lung 8 trial showed afatinib outperformed erlotinib with regard to both progression-free and overall survival in squamous cell lung cancer.

A new agent, AZD9291, showed promising clinical activity and progression-free survival in a study of patients with advanced stage, EGFR mutation-positive NSCLC.

Pembrolizumab demonstrated a 24.8% overall response rate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Elective neck lymph node surgery for patients with early oral cancer reduces the risk of cancer recurrence and improves survival.

Immediate ADT improved overall survival compared with delayed ADT in prostate cancer patients with a rising prostate-specific antigen level.

Researchers have identified a new histologic subset of metastatic castration-resistant prostate cancer that is refractory to androgen receptor inhibition.

An analysis of more than 34,000 5-year survivors of childhood cancer treated over 3 decades finds that modern treatments have reduced long-term mortality rates.

Data from the KEYNOTE-001 study showed that the anti–PD-1 antibody pembrolizumab produces durable responses in metastatic melanoma patients.

Due to the genetic heterogeneity observed in tumors of melanoma patients who developed resistance to BRAF inhibitors, assessing mechanisms of resistance has minimal potential to inform further treatment decisions.


By clicking Accept, you agree to become a member of the UBM Medica Community.